Johnson & Johnson announced FDA approval of a supplemental new drug application for Caplyta (lumateperone) for the prevention of relapse in schizophrenia, based on compelling long-term clinical data and reported by Drugs.com. This label expansion reinforces Caplyta’s role within Johnson & Johnson’s comprehensive neuropsychiatric therapy portfolio and addresses a critical unmet need in schizophrenia management.
Relapse Prevention as a Clinical Priority
Relapse represents one of the most disruptive challenges in schizophrenia management, undermining patient stability and triggering episodes of psychosis, hallucinations, and behavioral disturbances that can derail daily functioning. Schizophrenia affects approximately 2.8 million adults in the United States, yet approximately 40 percent remain inadequately treated. On average, adults with schizophrenia experience nine relapse episodes within a six-year period. The economic burden is substantial, with the societal cost of schizophrenia estimated at $366.8 billion in 2024. Reducing relapse risk therefore represents a critical goal in long-term disease management, helping preserve functioning, reduce caregiver strain, and break cycles of repeated hospitalization.
Robust Phase 3 Data
The approval was supported by data from a Phase 3, double-blind, randomized withdrawal trial evaluating Caplyta’s efficacy and safety over 26 weeks. Results demonstrated that Caplyta significantly reduced relapse risk by 63 percent compared with placebo, with 84 percent of patients remaining relapse-free over the six-month study period. The drug also significantly extended time to relapse versus placebo and delayed time to all-cause treatment discontinuation. Importantly, the safety profile remained consistent with previous clinical data, with no new safety concerns identified. Headache was the most common treatment-related adverse event, occurring in at least 5 percent of patients at rates at least twice that of placebo.
Favorable Safety and Tolerability Profile
A particular strength of Caplyta is its favorable tolerability profile compared to traditional antipsychotics. Short-term studies demonstrated that Caplyta produced minimal effects on weight change, metabolic parameters, and extrapyramidal symptoms, side effects often cited as reasons for treatment discontinuation. The Phase 3 randomized withdrawal study showed no clinically relevant increases in prolactin or cardiometabolic parameters. Long-term data from a 12-month open-label extension study revealed that patients experienced a mean weight loss of 2.05 kg over one year with sustained improvements or stability in metabolic parameters. Notably, Caplyta requires no titration, simplifying treatment initiation.
Mechanism and Clinical Implications
While its exact mechanism of action remains unknown, Caplyta is characterized by high serotonin 5-HT2A receptor occupancy combined with moderate dopamine D2 receptor occupancy at therapeutic doses. This unique neurochemical profile may contribute to its efficacy and favorable side effect profile.
“These Phase 3 results, showing significantly longer time to relapse with 84% remaining relapse free over 6-months, provide clinicians with another tool that can offer long-term stability for people living with schizophrenia,” noted Christoph U. Correll, M.D., Clinical Professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell.
Expanded Therapeutic Arsenal
Caplyta is now approved for use in adults as an adjunctive therapy with antidepressants for major depressive disorder and bipolar depression, as monotherapy for schizophrenia, and as adjunctive therapy with lithium or valproate. The drug is available in 42 mg, 21 mg, and 10.5 mg capsules. This label expansion significantly enhances treatment options for schizophrenia patients seeking long-term disease stability and improved quality of life.
